Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial (Q38058530)

27 August 2017

title

Bevacizumab in combination with IFN-α in metastatic renal cell carcinoma: the AVOREN trial (English)

1 reference

metastatic renal cell carcinoma

27 August 2017

1 reference

1 reference

1 reference

Bohuslav Melichar

1

1 reference

27 August 2017

Hana Procházková-Študentová

series ordinal

2

1 reference

27 August 2017

Denisa Vitásková

series ordinal

3

1 reference

27 August 2017

publication date

1 October 2012

1 reference

Expert Review of Anticancer Therapy

27 August 2017

published in

1 reference

27 August 2017

volume

12

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

1253-1261

1 reference

Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon‐α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Improving delivery of antineoplastic agents with anti-vascular endothelial growth factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

How can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.103

21 January 2018

Identifiers

DOI

10.1586/ERA.12.103

1 reference

27 August 2017

1 reference